Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Nasopharyngeal Carcinoma 2Carcinoma, Non-Small-Cell Lung 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Cancer 1Skin Neoplasms 1Non-small Lung Cancer 1Neuroendocrine Tumors 1Neoplasms 1Meningeal Carcinomatosis 1Local Advanced Non-small Cell Lung Cancer 1Liver Neoplasms 1Klatskin Tumor 1High-risk Renal Cell Carcinoma 1Gallbladder Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Breast Neoplasms 1Advanced Solid Tumor 1

Interventions

trastuzumab deruxtecan 1toripalimab 1pertuzumab 1pembrolizumab 1atezolizumab 1Trastuzumab 1Ramucirumab 1Paclitaxel 1Oxaliplatin 1Leucovorin 1Irinotecan 1Fluorouracil 1Etoposide 1Cetuximab 1Carboplatin 1Capecitabine 1Bevacizumab 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Solid Cancer × toripalimab × Clear all
NCT06771622 2026-02-04

Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors

FBD Biologics Limited

Phase 1/2 Active not recruiting
500 enrolled

Solid Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡